Our prospective study investigates the 3‐year trajectory of disease‐specific quality of life (QoL) using the PEmb‐QoL questionnaire, functional performance via 6‐min walk tests, and the 5‐year survival following acute pulmonary embolism (PE) and explores their association with patient demographics and clinical characteristics. We highlight that PE‐specific QoL improves over time despite no significant changes in cardiopulmonary performance.
1 January 2026 in Cardiology Research and Practice
Background: Atrioventricular canal defect (AVCD) is a congenital heart disease often associated with genetic changes, with a broad spectrum of anatomical patterns. Aim: We present a novel likely pathogenic variant of MYBPC3 in a proband with AVCD. Methods: A clinical and genetic evaluation was conducted on a one‐year‐old Iranian girl referred to our center with cardiac structural abnormalities and her family. Transthoracic echocardiography (TTE) and cardiac computed tomography (CT) were employed for clinical evaluation, and whole exome sequencing (WES), polymerase chain reaction (PCR), and Sanger sequencing were utilized for genetic analysis. Results: TTE revealed a ventricular and atrial septal defect (ASD), along with pulmonary hypertension (PH). The proband was diagnosed with AVCD through cardiac CT. WES identified a novel heterozygous MYBPC3 (NM_000256.3): c.3747_3748insGG; p.(Ile1250Glyfs∗82). Segregation analysis confirmed the presence of the same variant in the proband’s father, who was diagnosed with hypertrophic cardiomyopathy (HCM). Conclusion: We presented the first case of AVCD associated with a novel MYBPC3 variant, expanding the spectrum of cardiac anomalies linked to MYBPC3 mutations. The findings highlight the complexity and variable expression of MYBPC3 within affected family members.